Page last updated: 2024-11-05

troglitazone and Burkitt Lymphoma

troglitazone has been researched along with Burkitt Lymphoma in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Burkitt Lymphoma: A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Takenokuchi, M1
Saigo, K1
Nakamachi, Y1
Kawano, S1
Hashimoto, M1
Fujioka, T1
Koizumi, T1
Tatsumi, E1
Kumagai, S1

Other Studies

1 other study available for troglitazone and Burkitt Lymphoma

ArticleYear
Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
    Acta haematologica, 2006, Volume: 116, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Burkitt Lymphoma; Cell

2006